The next treatment-resistant depression paradigm

In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.

Host

⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Hans Eriksson, Chief Medical Officer, FundaMental Pharma

Steve Levine, Chief Patient Officer, Compass Pathways

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.